Bilchem Biotec Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 172.85%
- Profit Growth -1141.45%
- Ebitda -641.63%
- Net Worth -12.66%
- Total Assets -20.24%
About Bilchem Biotec
Bilchem Biotec Private Limited (BBPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 August 2006 and has a history of 18 years and six months. Its registered office is in Shimla, Himachal Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Om Sharma and Nandjee Prasad serve as directors at the Company.
Company Details
-
Location
Shimla, Himachal Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231HP2006PTC030541
-
Company No.
030541
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Aug 2006
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Himachal Pradesh
Industry
What products or services does Bilchem Biotec Private Limited offer?
Bilchem Biotec Private Limited offers a wide range of products and services, including Construction Service, Residential Construction Projects.
Who are the key members and board of directors at Bilchem Biotec?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Om Sharma
|
Director | 04-Aug-2006 | Current |
|
Nandjee Prasad
|
Director | 31-Jul-2010 | Current |
Financial Performance of Bilchem Biotec.
Bilchem Biotec Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 172.85% increase. The company also saw a substantial fall in profitability, with a 1141.45% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bilchem Biotec?
In 2018, Bilchem Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Quad Lifesciences Private LimitedOm Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bilchem Biotec?
Unlock and access historical data on people associated with Bilchem Biotec, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bilchem Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bilchem Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
